| Revista: | Revista de investigación clínica |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000453210 |
| ISSN: | 0034-8376 |
| Autores: | Jiménez Lima, Roberto1 Arango Bravo, Eder2 Galicia Carmona, Tatiana2 Lino Silva, Leonardo S3 Trejo Durán, Guadalupe E4 Alvarado Silva, Cristina5 Castañeda Renderos, Omar H6 Vanoye Carlo, Elva G7 Flores de la Torre, Celia8 Dueñas González, Alfonso2 Cetina Pérez, Lucely2 |
| Instituciones: | 1Universidad Nacional Autónoma de México, Facultad de Medicina, Ciudad de México. México 2Instituto Nacional de Cancerología, Departamento de Investigación Clínica, Ciudad de México. México 3Instituto Nacional de Cancerología, Departamento de Patología Oncológica, Ciudad de México. México 4Instituto Nacional de Cancerología, Departamento de Radioterapia, Ciudad de México. México 5Hospital Juárez de México, Departamento de Oncología Médica, Ciudad de México. México 6Hospital Universitario de Saltillo, Departamento de Oncología Médica, Saltillo, Coahuila. México 7Hospital General "Dr. Agustín O'Horán", Departamento de Ginecología Oncológica, Mérida, Yucatán. México 8INDESALUD, Centro Estatal de Oncología Campeche, Campeche. México |
| Año: | 2020 |
| Periodo: | Jul-Ago |
| Volumen: | 72 |
| Número: | 4 |
| Paginación: | 231-238 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico, descriptivo |
| Resumen en inglés | Cervical cancer (CC) is one of the most common gynecological tumors and an important health problem, especially in developing countries. The vast majority of patients in early stages are cured of the disease with surgical treatment and with concomitant chemoradiotherapy in locally advanced stages. However, in patients with recurrent, persistent, or metastatic cervical CC, the effectiveness of treatment is limited, except for the combination of chemotherapy based on platinum doublets plus bevacizumab, the treatment that has achieved the best results to date. Programmed cell death-1/PD ligand-1 (PD-1/PD-L1) inhibitors could be a novel and cutting-edge therapeutic option to improve clinical outcomes in this group of patients. Thus far, there are a few Phase I/II clinical trials that have assessed the usefulness of pembrolizumab and nivolumab in this group of patients; these include the KEYNOTE 028, KEYNOTE 158, and CHECKMATE 358 trials, in which clinical benefit has been proven with PD-1/PD-L1 inhibitors in recurrent, persistent, or metastatic CC, as second-line treatment. There are also some ongoing trials that could provide further evidence on the PD-1/PD-L1 pathway as a therapeutic target in CC. In this review, we will focus on the usefulness of these PD-1/PDL1 inhibitors in CC, as well as on trials that are still in the recruitment phase, to confirm their effectiveness in this clinical setting |
| Disciplinas: | Medicina |
| Palabras clave: | Oncología, Ginecología y obstetricia, Inmunología, Cáncer cervical, Inmunoterapia, Linfocitos T citotóxicos, Muerte celular programada, Anticuerpos monoclonales |
| Keyword: | Oncology, Gynecology and obstetrics, Immunology, Cervical cancer, Immunotherapy, Cytotoxic T lymphocytes, Programmed cell death, Monoclonal antibodies |
| Texto completo: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
